Nullifying drug-induced sensitization: behavioral and electrophysiological evaluations of dopaminergic and serotonergic ligands in methamphetamine-sensitized rats.
Repeated exposure to methamphetamine produces a persistent enhancement of the acute motor effects of the drug, commonly referred to as behavioral sensitization. Behavioral sensitization involves monoaminergic projections to several forebrain nuclei. We recently revealed that the ventral pallidum (VP) may also be involved. In this study, we sought to establish if treatments with antagonists or partial agonists to monoaminergic receptors could "reverse" methamphetamine-induced behavioral and VP neuronal sensitization. Behavioral sensitization was obtained in rats with five once-daily s.c. injections of 2.5mg/kg methamphetamine, an effect that persisted for at least 60 days. After the development of sensitization, 15 once-daily treatments of mirtazapine (a 5-HT(2/3), alpha(2) and H(1) antagonist), SKF38393 (D(1) partial agonist) or SCH23390 (dopamine D(1) antagonist) nullified indices of motor sensitization as assessed by measuring the motoric response to an acute methamphetamine challenge 30 days after the fifth repeated methamphetamine treatment. VP neurons recorded in vivo from methamphetamine-sensitized rats at the 30-day withdrawal time also showed a robust downward shift in the excitatory responses observed to an acute i.v. methamphetamine challenge in non-sensitized rats. This decreased excitatory effect was reversed by mirtazapine, but not by other antagonists that were tested. These data suggest a potential therapeutic benefit for mirtazapine in the treatment of methamphetamine addiction, and point to a possible role for the VP in the sensitization process to methamphetamine.
McDaid
J
J
Department of Pharmacology and Experimental Therapeutics, Loyola University Chicago Medical Center, 2160 South First Ave., Maywood, IL 60153-5515, USA.
Tedford
C E
CE
Mackie
A R
AR
Dallimore
J E
JE
Mickiewicz
A L
AL
Shen
F
F
Angle
J M
JM
Napier
T C
TC
D000200:Action Potentials / Q000187:drug effects; D018663:Adrenergic Agents / Q000008:administration & dosage / Q000494:pharmacology*; D000317:Adrenergic alpha-Antagonists / Q000008:administration & dosage / Q000494:pharmacology; D000818:Animals; D004298:Dopamine / Q000378:metabolism*; D004563:Electrochemistry / Q000379:methods; D005917:Globus Pallidus / Q000187:drug effects; D007650:Ketanserin / Q000008:administration & dosage / Q000494:pharmacology; D008124:Locomotion / Q000187:drug effects*; D008297:Male; D008694:Methamphetamine / Q000008:administration & dosage / Q000494:pharmacology*; D008803:Mianserin / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000494:pharmacology; D008839:Microelectrodes; D000078785:Mirtazapine; D051381:Rats; D017207:Rats, Sprague-Dawley; D011941:Receptors, Adrenergic / Q000187:drug effects; D017447:Receptors, Dopamine D1 / Q000187:drug effects; D011985:Receptors, Serotonin / Q000187:drug effects; D012701:Serotonin / Q000378:metabolism*; D012702:Serotonin Antagonists / Q000008:administration & dosage / Q000494:pharmacology
D018663:Adrenergic Agents; D000317:Adrenergic alpha-Antagonists; D011941:Receptors, Adrenergic; D017447:Receptors, Dopamine D1; D011985:Receptors, Serotonin; D012702:Serotonin Antagonists; D008803:Mianserin; D012701:Serotonin; D008694:Methamphetamine; D007650:Ketanserin; D000078785:Mirtazapine; D004298:Dopamine